Watch OPRX. Know when insiders buy.
One email the day a filing lands. Free.
OPRX
OptimizeRx Corp
7.89
+0.29 +3.82%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
48
WATCH · shorts 48
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $148.6MP/E 34.3DIV YIELD —FCF YIELD 12.35%REV TTM $98.7M −5.8%NET INCOME $4.6MNET CASH $4.4M52W 4.54 – 21.68SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $20.5M | −29.8% | 76.5% | −$88K | −$703K | −145.9% | -0.04 | $8.6M | $35K | $8.6M | Aug 13 |
| Q1 2026 · Mar 31 | $19.8M | −9.5% | 75.2% | $396K | −$495K | — | -0.03 | −$467K | $21K | −$488K | Aug 13 |
| Q4 2025 · Dec 31derived | $32.2M | −0.2% | 74.8% | $8.6M | $5M | — | 0.26 | $7.1M | $11K | $7.1M | Mar 12 |
| Q3 2025 · Sep 30 | $26.1M | +22.3% | 67.2% | $2M | $779K | — | 0.04 | $3.2M | $10K | $3.2M | Nov 7 |
| Q2 2025 · Jun 30 | $29.2M | +55.2% | 63.8% | $3.2M | $1.5M | — | 0.08 | $4.6M | $10K | $4.6M | Aug 13 |
| Q1 2025 · Mar 31 | $21.9M | +11.4% | 60.9% | −$2.1M | −$2.2M | — | -0.12 | $3.9M | $27K | $3.8M | Aug 13 |
| Q4 2024 · Dec 31derived | $32.3M | +13.9% | 68.1% | $3.6M | −$78K | — | 0.00 | $198K | $17K | $181K | Mar 12 |
| Q3 2024 · Sep 30 | $21.3M | +30.5% | 63.1% | −$8.6M | −$9.1M | — | -0.50 | $1.8M | $18K | $1.8M | Nov 7 |
| Q2 2024 · Jun 30 | $18.8M | — | 62.2% | −$3.7M | −$4M | — | -0.22 | $782K | $45K | $737K | Nov 7 |
| Q1 2024 · Mar 31 | $19.7M | — | 62.0% | −$5M | −$6.9M | — | -0.38 | $2.1M | $32K | $2.1M | Nov 7 |
| Q4 2023 · Dec 31derived | $28.4M | — | 62.9% | −$10.9M | −$4.1M | — | -0.24 | −$6.3M | $5K | −$6.3M | Mar 20 |
| Q3 2023 · Sep 30 | $16.3M | — | 60.0% | −$3.6M | −$2.9M | — | -0.17 | $1.5M | $33K | $1.4M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $109.4M | 67.3% | $11.7M | $5.1M | 4.7% | 0.27 | $18.7M | $58K | $18.7M | — | — |
| FY2024 · to Dec 31 | $92.1M | 64.5% | −$13.7M | −$20.1M | -21.8% | -1.10 | $4.9M | $112K | $4.8M | — | — |
| FY2023 · to Dec 31 | $71.5M | 60.0% | −$26.4M | −$17.6M | -24.6% | -1.03 | −$7.2M | $87K | −$7.3M | $7.5M | — |
| FY2022 · to Dec 31 | $62.5M | 62.4% | −$12.3M | −$11.4M | -18.3% | -0.64 | $10.7M | $81K | $10.6M | $20M | — |
| FY2021 · to Dec 31 | $61.3M | 58.1% | $361K | $378K | 0.6% | 0.02 | $726K | $100K | $626K | — | — |
| FY2020 · to Dec 31 | $43.3M | 55.7% | −$2.1M | −$2.2M | -5.1% | -0.15 | −$6.3M | $68K | −$6.4M | — | — |
Every number comes from OptimizeRx Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.